Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Oncology Quality, Characterization and Assessment of Real-World Data (QCARD) InitiativeOncology Center of Excellence Oncology Quality, Characterization and Assessment of Real-World Data (QCARD) Initiative
  
  					Facilitating High-Quality Early RWD Study Proposals in Oncology
	
    Share
    Post
    Linkedin

    Email
    PrintBackground

The 21st Century Cures Act highlights the opportunity to modernize trial design and expand evidence generation, including the use of real-world data for potential regulatory purposes. Use of RWD is increasing in regulatory submissions, with the majority supporting oncology indications.

Purpose

The Oncology Quality, Characterization and Assessment of Real-World Data (QCARD) initiative was designed to facilitate effective communication between Sponsors and FDA Oncology reviewers to improve review efficiency for early RWD study proposals. The QCARD initiative was a collaboration between the OCE and the Reagan-Udall Foundation to evaluate essential data elements that could provide a basis for characterizing the data source(s) and design of a RWD study. Importantly, the Oncology QCARD is intended to improve the quality of initial *study proposals* and is not an evaluation of the quality of real-world data submitted within a regulatory review.

The Oncology QCARD initiative created a set of key design and data source elements that helped to inform information requests from oncology review teams to facilitate meaningful feedback on proposed RWD studies. FDA is making the common data elements from those information requests available for sponsor awareness in Figure 1. Sponsors should follow recommendations consistent with published FDA RWE guidance and scientific best practices throughout protocol development. Formal protocol and statistical analysis plans should be finalized and submitted to FDA prior to study initiation and conduct of any analyses.

When submitting early proposals that contain RWD for review in oncology, sponsors should include sufficient information to support study characterization. Considering the inclusion of commonly requested data elements reflected in Figure 1 may be helpful. While an initial foundation, the elements in Figure 1 are  non- exhaustive as there may be additional important design or data source information not listed or elements listed that may not be relevant to the particular study proposal. Please include any relevant references where appropriate. If you are planning to submit an early proposal containing RWD for review in oncology, please contact the appropriate review division to discuss your specific drug development program.

**Figure 1:**

**Common Data Elements for Early Proposals of Oncology Studies Using RWD**

**Overall Study and RWD Source Information**
			**Study Design Parameters**
			**Statistical Plan**
			**Data**Study Sponsor
				Real World Data Source Provider
				Data Analyst(s)
				Regulatory history of RWD proposal
				Study Status (Planned, Ongoing)
				Regulatory or Related Purpose(s)
				Study Question(s)/ Objective(s)
				RWD Source(s)
				Including any Linked Data
				Care Setting (as applicable)
				Brief RWD Source Description
				Rationale for RWD Source Selection
			**Data Temporality**
			• Complete Original Source Data Years Available
			• Study Period
			• Data of Data Extraction (Analytic Dataset) 
			• Initial Design Diagram (Graphical depiction of study design)

			**Population**
			• Disease or Condition for Intended Use
			• Indication Statement
			• Relevant Biomarkers 
			• Study Eligibility Criteria
			• Expected Study Sample Size
			• External Validity: Representativeness of the source data to the intended use population (as applicable).

			**Exposure**
			• Type of Medical Product Exposure
			• Medical Product Exposure of Interest
			• Description of Exposure Ascertainment Method
			• Index Date Definition for Exposure Group

			**Comparator**
			• Comparator(s) of Interest
			• Description of the Comparator Ascertainment Method
			• Index Date 
			• Definition for Comparator Group

			**Endpoints**
			• Primary Clinical Endpoint(s) Definition
			• Secondary Clinical Endpoint(s) Definition

			**Key Covariates**
			• Include any key covariates
			Brief summary of the planned main statistical analyses of the primary endpoint(s)
			• Source Data Availability and Auditing Plan
			• Data Provenance Documentation Plan 
			• Data Quality Plan
			• Missing DataQuestions

Please contact OCERWE@fda.hhs.gov for any questions on Oncology QCARD or Oncology RWD regulatory questions.

Further Information

Oncology Real World Evidence Program
	FDA Voices: Facilitating Review of Real-World Data Studies: The Oncology QCARD Initiative

                                                                                  Content current as of:
      06/27/2023Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop